In the present prospective study, we assessed age, HBP, BMI, LVEF, LVESV, Sm and Emwave, LA, E/A and NT-proBNP level as possible predictors of trastuzumab-relatedcardiac dysfunction in HER-2 positive breast cancer patients undergoingpost-anthracycline adjuvant trastuzumab therapy. This evidence concerns the gene ERBB2 and breast carcinoma.